NCT07180264View on ClinicalTrials.gov

Trastuzumab Deruxtecan in Advanced Breast Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

118

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2029

Conditions
Advanced Breast Cancer
Interventions
DRUG

Trastuzumab deruxtecan

Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.

Trial Locations (1)

200127

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

Wenjin Yin

OTHER